Comerota's rationale paper argues that iliofemoral DVT patients have severe postthrombotic morbidity on anticoagulation aloneβciting a 2.4-fold higher recurrence rate vs femoropopliteal DVT . Notably, the paper itself acknowledges the ACCP guideline evidence was weak (Grade 2B)βa candid framing that anticipates the trial's necessity.
The described design is rigorous for its era: phase-3, multicenter (30β50 US centers), randomized, open-label but assessor-blinded, stratified by DVT extent, with validated instruments (Villalta, VEINES-QOL, SF-36, Venous Clinical Severity Score) and objective duplex assessment of patency and valve function .
Conflict of interest is material: the author is a trial PI and Covidien consultant, and the trial received device/pharma support (Covidien, Genentech, Medrad, BSN Medical) . The prose is advocacy-flavored (βessentially a normal life for manyβ). Supporting evidence cited (registry data, retrospective series) was non-randomized; a narrative review of the era reported thrombolysis achieving complete thrombus resolution in ~45% vs ~4% with heparin across 13 studies, but with major bleeding at catheter sites (~11% subset) and calls for RCTs . The paper omits any quantified bleeding-risk comparison, a key blind spot later partially borne out.
The paper's own falsification path: CDT failing to significantly reduce postthrombotic syndrome at 24 months. Contextual series (e.g., retrospective stent-plus-thrombolysis cohorts with 75% 1-year primary patency) were inherently uncontrolled . Confidence: moderateβthis is a pre-results rationale; the paper's claims were hypotheses, and readers should consult the published ATTRACT results (2017) rather than this advocacy document for efficacy conclusions.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.